Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00617461 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
A Phase 2 study of Neuralgia, Postherpetic, sponsored by XenoPort.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
- 20
- Study locations
NCT00617461 is a Phase 2 study of Neuralgia, Postherpetic that has completed, run by XenoPort. The registered enrollment target is 96 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT00617461, a Phase 2 study of Neuralgia, Postherpetic, has completed, sponsored by XenoPort.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is evaluate the difference between two doses of gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn, on pain associated with post-herpetic neuralgia.
Conditions Studied
Interventions
- DRUG GEn 1200mg/day
- DRUG GEn 3600mg/day
Study Locations (20)
Florida
- GSK Investigational Site - Bradenton
- GSK Investigational Site - Chipley
- GSK Investigational Site - Daytona Beach
- GSK Investigational Site - Fort Myers
- GSK Investigational Site - Gainesville
- GSK Investigational Site - Marianna
- GSK Investigational Site - Miami Springs
- GSK Investigational Site - Naranja
- GSK Investigational Site - South Miami
- GSK Investigational Site - Tallahassee
- GSK Investigational Site - Tampa
- GSK Investigational Site - Tampa
California
- GSK Investigational Site - Oxnard
- GSK Investigational Site - Roseville
- GSK Investigational Site - San Francisco
Georgia
- GSK Investigational Site - Decatur
- GSK Investigational Site - Marietta
Arizona
- GSK Investigational Site - Phoenix
Illinois
- GSK Investigational Site - Chicago
Indiana
- GSK Investigational Site - Terre Haute
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00617461
The ClinicalTrials.gov registry entry for NCT00617461 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is XenoPort, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuralgia, Postherpetic appearing as the primary indexed condition, and to 2 interventions - of which GEn 1200mg/day is the first listed.
NCT00617461 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT00617461 about?
NCT00617461 is a clinical study titled "A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment". The purpose of this study is evaluate the difference between two doses of gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn, on pain associated with post-herpetic neuralgia.
What is the current status of trial NCT00617461?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2008-03. Estimated completion is 2009-07.
What conditions does trial NCT00617461 study?
This clinical trial studies the following conditions: Neuralgia, Postherpetic.
What interventions are being tested in trial NCT00617461?
The interventions under investigation include: GEn 1200mg/day (DRUG), GEn 3600mg/day (DRUG).
Who is sponsoring clinical trial NCT00617461?
This trial is sponsored by XenoPort, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00617461 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.